99mTc-rituximab tracer injection for guiding internal mammary sentinel lymph nodes biopsy in primary breast cancer: A prospective observational study
ObjectiveTo explore the use of 99mTc-rituximab tracer injection for internal mammary sentinel lymph node (IM-SLN) detection in patients with primary breast cancer.MethodsThis prospective observational study enrolled female patients with primary breast cancer between September 2017 and June 2022 at F...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1100077/full |
| _version_ | 1811167165430104064 |
|---|---|
| author | Wenxin Chen Wenxin Chen Wenxin Chen Yaodong Su Yaodong Su Yaodong Su Hui Zhang Hui Zhang Yu Zhang Yu Zhang Yu Zhang Lin Zhu Lin Zhu Mengbo Lin Mengbo Lin Zhiyi Lin Zhiyi Lin Zhiyi Lin Mingdian Yu Shengping Yang Yanmin Zhang |
| author_facet | Wenxin Chen Wenxin Chen Wenxin Chen Yaodong Su Yaodong Su Yaodong Su Hui Zhang Hui Zhang Yu Zhang Yu Zhang Yu Zhang Lin Zhu Lin Zhu Mengbo Lin Mengbo Lin Zhiyi Lin Zhiyi Lin Zhiyi Lin Mingdian Yu Shengping Yang Yanmin Zhang |
| author_sort | Wenxin Chen |
| collection | DOAJ |
| description | ObjectiveTo explore the use of 99mTc-rituximab tracer injection for internal mammary sentinel lymph node (IM-SLN) detection in patients with primary breast cancer.MethodsThis prospective observational study enrolled female patients with primary breast cancer between September 2017 and June 2022 at Fujian Provincial Hospital. The participants were divided into the peritumoral group (two subcutaneous injection points on the surface of the tumor), two-site group (injections into the glands at 6 and 12 o’clock around the areola area), and four-site group (injections into the gland at 3, 6, 9, and 12 o’clock around the areola area). The outcomes were the detection rates of the IM-SLNs and axillary sentinel lymph nodes (A-SLNs).ResultsFinally, 133 patients were enrolled, including 53 in the peritumoral group, 60 in the two-site group, and 20 in the four-site group. The detection rate of the IM-SLNs in the peritumoral group (9.4% [5/53]) was significantly lower than in the two-site (61.7% [37/60], P<0.001) and four-site (50.0% [10/20], P<0.001) groups. The detection rates of A-SLNs among the three groups were comparable (P=0.436).ConclusionThe two-site or four-site intra-gland injection of 99mTc-rituximab tracer might achieve a higher detection rate of IM-SLNs and a comparable detection rate of A-SLNs compared with the peritumoral method. The location of the primary focus has no impact on the detection rate of the IM-SLNs. |
| first_indexed | 2024-04-10T16:04:36Z |
| format | Article |
| id | doaj.art-3b42d8b6ebfa42eea6732786eb50cd3c |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T16:04:36Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-3b42d8b6ebfa42eea6732786eb50cd3c2023-02-10T05:37:54ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-02-011310.3389/fonc.2023.1100077110007799mTc-rituximab tracer injection for guiding internal mammary sentinel lymph nodes biopsy in primary breast cancer: A prospective observational studyWenxin Chen0Wenxin Chen1Wenxin Chen2Yaodong Su3Yaodong Su4Yaodong Su5Hui Zhang6Hui Zhang7Yu Zhang8Yu Zhang9Yu Zhang10Lin Zhu11Lin Zhu12Mengbo Lin13Mengbo Lin14Zhiyi Lin15Zhiyi Lin16Zhiyi Lin17Mingdian Yu18Shengping Yang19Yanmin Zhang20Department of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, ChinaDepartment of Nuclear Medicine, Fujian Provincial Hospital, Fuzhou, ChinaFujian Research Institute of Nuclear Medcine, Fuzhou, ChinaDepartment of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, ChinaDepartment of Nuclear Medicine, Fujian Provincial Hospital, Fuzhou, ChinaFujian Research Institute of Nuclear Medcine, Fuzhou, ChinaDepartment of Oncology Surgery, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, ChinaDepartment of Oncology Surgery, Fujian Provincial Hospital, Fuzhou, ChinaDepartment of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, ChinaDepartment of Nuclear Medicine, Fujian Provincial Hospital, Fuzhou, ChinaFujian Research Institute of Nuclear Medcine, Fuzhou, ChinaDepartment of Ultrasonic Diagnostics, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, ChinaDepartment of Ultrasonic Diagnostics, Fujian Provincial Hospital, Fuzhou, ChinaDepartment of Oncology Surgery, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, ChinaDepartment of Oncology Surgery, Fujian Provincial Hospital, Fuzhou, ChinaDepartment of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, ChinaDepartment of Nuclear Medicine, Fujian Provincial Hospital, Fuzhou, ChinaFujian Research Institute of Nuclear Medcine, Fuzhou, ChinaDepartment of Nuclear Medicine, Fujian Provincial Hospital, Fuzhou, ChinaDepartment of Nuclear Medicine, Fujian Provincial Hospital, Fuzhou, ChinaDepartment of Nuclear Medicine, Fujian Provincial Hospital, Fuzhou, ChinaObjectiveTo explore the use of 99mTc-rituximab tracer injection for internal mammary sentinel lymph node (IM-SLN) detection in patients with primary breast cancer.MethodsThis prospective observational study enrolled female patients with primary breast cancer between September 2017 and June 2022 at Fujian Provincial Hospital. The participants were divided into the peritumoral group (two subcutaneous injection points on the surface of the tumor), two-site group (injections into the glands at 6 and 12 o’clock around the areola area), and four-site group (injections into the gland at 3, 6, 9, and 12 o’clock around the areola area). The outcomes were the detection rates of the IM-SLNs and axillary sentinel lymph nodes (A-SLNs).ResultsFinally, 133 patients were enrolled, including 53 in the peritumoral group, 60 in the two-site group, and 20 in the four-site group. The detection rate of the IM-SLNs in the peritumoral group (9.4% [5/53]) was significantly lower than in the two-site (61.7% [37/60], P<0.001) and four-site (50.0% [10/20], P<0.001) groups. The detection rates of A-SLNs among the three groups were comparable (P=0.436).ConclusionThe two-site or four-site intra-gland injection of 99mTc-rituximab tracer might achieve a higher detection rate of IM-SLNs and a comparable detection rate of A-SLNs compared with the peritumoral method. The location of the primary focus has no impact on the detection rate of the IM-SLNs.https://www.frontiersin.org/articles/10.3389/fonc.2023.1100077/fullbreast cancer99mTc-rituximabsentinel lymph nodeinternal mammary lymph nodesingle photon emission computed tomography/computed tomographybiopsy |
| spellingShingle | Wenxin Chen Wenxin Chen Wenxin Chen Yaodong Su Yaodong Su Yaodong Su Hui Zhang Hui Zhang Yu Zhang Yu Zhang Yu Zhang Lin Zhu Lin Zhu Mengbo Lin Mengbo Lin Zhiyi Lin Zhiyi Lin Zhiyi Lin Mingdian Yu Shengping Yang Yanmin Zhang 99mTc-rituximab tracer injection for guiding internal mammary sentinel lymph nodes biopsy in primary breast cancer: A prospective observational study Frontiers in Oncology breast cancer 99mTc-rituximab sentinel lymph node internal mammary lymph node single photon emission computed tomography/computed tomography biopsy |
| title | 99mTc-rituximab tracer injection for guiding internal mammary sentinel lymph nodes biopsy in primary breast cancer: A prospective observational study |
| title_full | 99mTc-rituximab tracer injection for guiding internal mammary sentinel lymph nodes biopsy in primary breast cancer: A prospective observational study |
| title_fullStr | 99mTc-rituximab tracer injection for guiding internal mammary sentinel lymph nodes biopsy in primary breast cancer: A prospective observational study |
| title_full_unstemmed | 99mTc-rituximab tracer injection for guiding internal mammary sentinel lymph nodes biopsy in primary breast cancer: A prospective observational study |
| title_short | 99mTc-rituximab tracer injection for guiding internal mammary sentinel lymph nodes biopsy in primary breast cancer: A prospective observational study |
| title_sort | 99mtc rituximab tracer injection for guiding internal mammary sentinel lymph nodes biopsy in primary breast cancer a prospective observational study |
| topic | breast cancer 99mTc-rituximab sentinel lymph node internal mammary lymph node single photon emission computed tomography/computed tomography biopsy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1100077/full |
| work_keys_str_mv | AT wenxinchen 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT wenxinchen 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT wenxinchen 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT yaodongsu 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT yaodongsu 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT yaodongsu 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT huizhang 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT huizhang 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT yuzhang 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT yuzhang 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT yuzhang 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT linzhu 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT linzhu 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT mengbolin 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT mengbolin 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT zhiyilin 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT zhiyilin 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT zhiyilin 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT mingdianyu 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT shengpingyang 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy AT yanminzhang 99mtcrituximabtracerinjectionforguidinginternalmammarysentinellymphnodesbiopsyinprimarybreastcanceraprospectiveobservationalstudy |